An unceremonious dumping ground for the sort of horror movies most people can live without, Q1 has long functioned as a graveyard for the genre. The top of the year is when many studios quietly offload their nastiest programming misfires, pushing through contractual obligations and churning out projects they don’t really “believe” in — before movie season can fully spring forward.
Which is exactly why 2026 has felt so… weird. From January to March, half-baked nightmares were indeed buried under a thick haze of post-holiday family fare. But while experienced horror fans prepared for the worst, the titles that actually came to theaters were good, for the most part. Not universally, and not without some objective disasters (“Return to Silent Hill” is every bit the slog you feared!), but with a higher batting average than we’ve come to expect from this time of year.
A crowning jewel among several big hits with critics, director Nia DaCosta’s soul-shaking “28 Years Later: The Bone Temple” swung for the fences creatively — even as it struggled to theatrically recoup massive production costs. Meanwhile, a series of scrappy and surprising indies, including “Iron Lung,” “Forbidden Fruits,” and “Mother of Flies,” delivered comparably impressive pathos on much leaner budgets. That tension, between artistic vitality and financial uncertainty, more or less defined the whole quarter.
Although the quality of the films themselves often exceeded expectations, the box office told a more complicated story. Big bets didn’t always pay off (“Bone Temple” being the most notable flop, earning $58 million globally against a reported $63 million budget before marketing), and horror as a whole saw a dip in profitability compared to this same cycle last year. On the flip side, “Scream 7” set a new franchise record at Paramount, once again proving horror IP can be a serious tentpole affair (even amid controversy).
Commercially uneven, and a bit confusing in terms of what viewers honestly want from horror entertainment these days, our year in fear isn’t even close to over. Still to come in 2026, Q2 will test the market with Lee Cronin’s “The Mummy,” Damian McCarthy’s “Hokum,” Curry Barker’s “Obsession,” the Wayans’ “Scary Movie 6,” and more misadventures poised to build on genre momentum soon.
Here are six key takeaways from Q1 at the 2026 horror movie box office.
1. One Ghostface to Rule Them All
If Q1 2026 proved anything, it’s that slasher movies remain a star-driven, or at least brand-driven, sport. “Scream 7” performed well, earning $118.9 million domestically and $85.4 million internationally. The sequel accounted for more than a third of the horror genre’s entire haul this quarter and set a new franchise record in the process, besting previous series’ champion “Scream 6.”
The gap between “Scream 7” and almost everything else that’s come out this year is kind of staggering. Original screenwriter Kevin Williamson made his “Scream” directorial debut here — bringing in nearly twice as much as the next biggest horror hit, Sam Raimi’s original “Send Help,” which made a total of $94 million at the Q1 box office.
In a period defined by inconsistency, Ghostface was arguably the one “sure thing” in horror. The masked killer’s latest spree made more than four times what the rest of the top-five genre contenders earned over the last three months. Looking ahead, Q2 will be about stress-testing legacy dominance in part.
Also at Paramount, “Scary Movie 6” will tap into another nostalgic audience, albeit via a much broader comedic lane. “Lee Cronin’s The Mummy” also aims to demonstrate that revered IP can be an “event” when it’s thoroughly reimagined. If either film overperforms financially, its success will indicate fans aren’t just loyal to “Scream,” but hungry as ever for the horror concepts they already know and love.
2. The Middle Class of Horror Was Basically M.I.A.
What’s more concerning than any one horror flop is the shape of the genre’s overall curve in Q1. After the top few titles, the numbers fall off a cliff. The median horror gross this quarter was around $7 million — meaning most of these movies barely registered with consumers despite a wide theatrical release.
Lionsgate’s “The Strangers: Chapter 3,” Maggie Gyllenhaal’s “The Bride!” for Warner Bros., and Cineverse’s calamitous “Return to Silent Hill” adaptation all opened on thousands of screens, but largely landed with a shrug. Even something like “Ready or Not 2: Here I Come,” a sequel to the famously beloved cult hit from the Radio Silence duo, has struggled to break out beyond $17 million.
Of course, there’s still money at the top and signs of life at the bottom. But those dependable “mid-tier” genre movies that the horror industry used to crank out with ease? Those are looking increasingly threatened — if not outright endangered — in 2026.
Pivot to staffing, and that anxiety isn’t theoretical.
One of the bigger behind-the-scenes developments this quarter was Sam Zimmerman departing Shudder for Blumhouse. It’s a move that feels like it could shift where the future of indie horror development begins. The AMC-owned specialty streaming service has long been home to curator-driven horror films, all with a formidable genre presence. But Blumhouse has built a much bigger business scaling that sensibility into something arguably less prestigious but more commercially reliable.
That makes Q2 especially interesting for original horror titles, like Damian McCarthy’s “Hokum” (Neon) and Curry Barker’s “Obsession” (Focus Features). Those two feel like classic middle bets, and if they can break out at the box office even modestly, their success should signal that audiences haven’t abandoned this range forever. They’ve just become more selective about what merits the time and price.
3. Big Artistic Swings Still Don’t Guarantee Big Returns
No movie embodied Q1’s creative/commercial disconnect better than “28 Years Later: The Bone Temple.” That is the kind of ambitious, auteur-driven spectacle that horror fans are always begging studios to bankroll. And to Alex Garland and Danny Boyle’s credit, it exists.
But audiences didn’t show up in the numbers Sony had hoped for with “Bone Temple”, dwindling spectacularly compared to the draw managed by Garland’s earlier “28 Years Later” in 2025. Despite a wide release and major recognition of its intellectual property, the generally lauded sequel stalled at $25.1 million domestically and $33.2 million internationally. That’s not nothing, but for a project of this scale, it’s a tough pill to swallow. (Suffice to say, fans should feel lucky the next sequel is moving ahead as planned.)
The takeaway here isn’t that audiences don’t “want” bold artistic visions of horror. Rather, it’s that those kinds of cinematic experiments are still a gamble, and not one that the box office consistently rewards. Enter “The Mummy” (again!) for Warner Bros., which could split the difference between “big swing” and “four-quadrant” accessibility. Should it connect now — especially with players like Blumhouse absorbing even more creative leadership in the space — it could prove instructive across trends, studios, and slates.
If it doesn’t? You can expect even safer, even cheaper, even more boring IP plays in horror.
4. YouTubers Sure Do Look Like the Future of Horror…
One of the more fascinating hits of the quarter was “Iron Lung,” which pulled in nearly $50 million worldwide. It outdid several more traditional studio offerings in the process, and that result is even more interesting when you consider where the movie came from. Known as Markiplier on YouTube, filmmaker Mark Fischbach didn’t just set a new bar for project awareness; he brought a mobilized audience that spent real money supporting him, and the indie video game his debut feature adapts, at the box office.
Meanwhile, smaller-scale gaming titles, like Shudder’s ill-received “The Mortuary Assistant,” point to a pipeline where internet-native horror can generate sincere curiosity — even when it’s done poorly. We’re not living a source material revolution yet, but if digital creators can open movies at this level, how long before major Hollywood figures start chasing that kind of do-it-yourself pipeline more aggressively, too?
No doubt Q2 will press the issue, and if A24’s “Backrooms” gains enough traction, we could be looking at the early stages of a new IP feeder system. Think YouTube, indie games, and more internet or social media artifacts functioning as de facto development labs for low-budget horror flicks. (Freaky, huh?)
5. January and February Were Strong, but March… Collapsed?
For a quarter that’s typically disappointing, early 2026 was shockingly front-loaded with well-received horror movies. January and February accounted for the overwhelming majority of the genre’s revenue, with their respective totals buoyed by hits like “Scream 7,” “Send Help,” “Iron Lung,” and “Primate.”
Then, March hit, and the box office got way, way quieter. Outside of a few hidden gems, including “They Will Kill You” and “Forbidden Fruits,” horror mostly ceded its screens to other releases last month. That could change quickly in Q2, though, with the release calendar shaping up to be more evenly distributed but still very busy the first few weeks of spring. In 2026, studios are still treating horror as a year-round attraction instead of a seasonal afterthought. And if those films can sustain themselves even deeper into the financial quarter next year, they may finally debunk the “Q1 dumping ground” for good.
6. Execution Still Matters Way More Than Popular IP
If “Scream 7” is the high end of what recognizable horror properties can do, “Return to Silent Hill” is the cautionary tale on the other side of the spectrum. Despite literal decades of brand awareness and a 2,000-screen release, Cineverse’s brutally bad video game adaptation limped to just $5.5 million domestically. “The Strangers: Chapter 3” didn’t fare much better for Lionsgate, while newer or less traditional IP (like “Iron Lung”) managed to carve out much stronger audience interest.
Horror fans will absolutely show up for legacy IP, but only when they trust it. Familiarity alone isn’t enough anymore, and if anything, this year’s surprisingly strong start in genre film should raise the bar for all horror movies going forward. That brings us to Q2 2026… and a fresh set of scary questions.
Can “The Mummy” rebuild trust in a long-dormant monster brand? Can “Scary Movie 6” prove there’s still a healthy American appetite for crude and crass horror parody? Can original titles, like the bone-chilling “Hokum,” find the right artistic homes to haunt this May? The answers will go a long way toward defining what “bankable horror” means today. But for now, it’s a query looming over the rest of the year.